Officers of the British Thyroid Association

Professor Krishna Chatterjee

President - Professor V Krishna Chatterjee FRS FMedSci


Krishna Chatterjee, Professor of Endocrinology at the University of Cambridge, undertakes research at the interface of basic science and clinical medicine, which aims to advance fundamental knowledge of the thyroid axis.


His group studies rare and unusual disorders of thyroid hormone action, including Resistance to Thyroid Hormone mediated by defective thyroid hormone receptor beta or alpha; and a multisystem disease with deficiency of human selenocysteine-containing proteins, which affects thyroid hormone metabolism. He seeks to translate discoveries into better diagnosis and therapy of both rare and common thyroid disorders.




  • Dr Carla Moran, Secretary, BTA

Secretary -  Dr Carla Moran MB PhD


Dr Carla Moran is a Consultant Endocrinologist at the Institute of Metabolic Science, University of Cambridge and Addenbrookes Hospital, Cambridge, UK. After completing her specialist training in Endocrinology, Diabetes Mellitus & general internal medicine she undertook a fellowship in thyroid disease at Addenbrooke’s Hospital & the University of Cambridge, during which time she obtained her PhD degree, characterising humans aspects of rare forms of insensitivity to thyroid hormone.


In 2014, she was appointed as a consultant endocrinologist at Addenbrooke’s Hospital and now provides the specialist thyroid service there; services include thyroid cancer clinics, thyroid FNA & ultrasound clinics, thyroid disease in pregnancy clinic, rare thyroid disorder clinic and a general thyroid clinic.


She also directs a national referral service for patients with unusual thyroid function tests due to assay artefact or rare thyroid disease, including TSH secreting pituitary tumours, familial dysalbuminaemic hyperthyroxinaemia and RTH.


Her ongoing research involves characterisation of novel aspects of Resistance to Thyroid Hormone (RTH) mediated by defective beta form of the thyroid hormone receptor, their metabolic phenotype. She continues to investigate and treat patients suspected or confirmed to have RTHa, a newly described form of RTH, and unusual cases of TH resistance, such as that mediated by selenoprotein deficiency.